All In Biotech

Drug Trial Radar · NCT07905131

A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer

M-POP: A Phase Ib/II Open Label Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Jan 15, 2027

Primary completion

Jun 30, 2029

Study completion Jun 30, 2031

Sponsor

Lead sponsor
Daniel Nussbaum, M.D.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bristol-Myers Squibb
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, feasibility, and recommended dose of navlimetostat (BMS-986504) combined with mFOLFIRINOX before and after surgery in patients with localized pancreatic cancer with MTAP deletion.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • NavlimetostatDrug

    Investigational, small molecule anticancer agent being developed for the treatment of malignancies with homozygous deletion of the MTAP gene.

  • mFOLFIRINOX Treatment RegimenDrug

    Chemotherapy regimen composed of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse EventsTime frame: Up to 15 months
  2. Recommended phase 2 dose of navlimetostat, as measured by the number of participants who experience a dose limiting toxicity during the first cycle of the phase 1b portion of the studyTime frame: Dose limiting toxicities are assessed throughout the first 28 days on combination treatment.
  3. Feasibility of perioperative navlimetostat combined with mFOLFIRINOXTime frame: Measured from the start of study treatment with navlimetostat through 14 days after surgery.
  4. Severity of Adverse EventsTime frame: Up to 15 months
  5. Incidence of dose limiting toxicitiesTime frame: The first 28 days of combination treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke University

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.